Milestone Pharmaceuticals Inc (MIST) Stock Price, Quote & News

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a...

Industry: Biotechnology

Sector: Healthcare

Phone: 514 336 0444

Website: www.milestonepharma.com

Address:

1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada

MarketBeat May. 13 at 6:11 PM

https://marketbeat.com/a/8652816/ $MIST Milestone Pharmaceuticals Q1 Earnings Call Highlights

0 · Reply

doctorhak May. 13 at 5:57 PM

$MIST PIP has NEVER been studied outpatient, double blind, placebo. It’s NOT even a viable alternative for these patients who as a group respond better to earlier intervention. Any adverse event from PIP will no doubt be met with medical malpractice. So best of luck saving pennies. Knowledgeable providers know that PIP is off label. That’s a real risk to outpatient unmonitored therapy. Furthermore have any of you ever experienced tachycardia personal or attempted to treat it? WTF do you really know about the medical condition?

0 · Reply

TheYoungGeologist May. 13 at 5:57 PM

$MIST now have 10000 shares in my brokerage and 7000 in my Roth IRA

1 · Reply

Wut_About_Bob May. 13 at 5:32 PM

$MIST Blocking this obvious short. He has a shady handle name, and all of his posts are negative. It's quite obvious he hasn't researched the organization with most of what he has said. Block those who appear on a board to intentionally deceive.

0 · Reply

Amb8675309 May. 13 at 5:18 PM

$MIST really it’s a binary outcome for the next earnings call hiding inside of a slow, cash burn problem

0 · Reply

Amb8675309 May. 13 at 5:17 PM

$MIST the biggest driver for the share price will be if we get to see that 2000 to 3000 scripts on the next earning call

1 · Reply

Bolekjol May. 13 at 4:43 PM

$MIST now it will be a lot of focus on afib updates, enrollment etc. It will multiply before readouts afib deal is huge with very high probability of success. Just load the deeps when can and let it run.

0 · Reply

CashisKing_ May. 13 at 4:43 PM

$MIST when are we expecting china aproval?

1 · Reply

kellymone2 May. 13 at 4:36 PM

$MIST told ya. Panic doesn't bring anything.

0 · Reply

KilroyPicks May. 13 at 4:26 PM

$MIST - I would reasonably expect revenue between $700,000 to $1.1 million for Q2. Q3 I would expect a revenue range between $2.2 Million and $3.2 Million and Q4 between $4 Million and $5.5 Million. Full year revenue between $7.13 Million and $10 Million on the high side. Hopefully the scripts accelerate faster than I predict. Based on my expectations the scripts volume needed are as follows. Q2 - 1,400 to 2,200 Q3 - 4,400 to 6,400 Q4 - 8,000 to 11,000

1 · Reply

Milestone Pharmaceuticals reports Q1 EPS (20c), consensus 19c

May 13, 2026, 8:30 AM EDT - 8 hours ago

Milestone Pharmaceuticals Earnings Call Transcript: Q1 2026

May 13, 2026, 7:11 AM EDT - 9 hours ago

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026, 8:00 AM EDT - 7 days ago

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

Apr 13, 2026, 3:45 PM EDT - 4 weeks ago

Milestone Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-10T12:06:08.000Z - 4 weeks ago

Milestone Pharmaceuticals provides details on RESET-PSVT trial

Apr 10, 2026, 8:00 AM EDT - 4 weeks ago

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

2026-04-10T09:35:10.000Z - 4 weeks ago

Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James

2026-04-09T20:37:44.000Z - 4 weeks ago

Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James

Apr 7, 2026, 8:30 AM EDT - 5 weeks ago

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 2, 2026, 8:00 AM EDT - 5 weeks ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-31T12:09:12.000Z - 6 weeks ago

Milestone Pharmaceuticals announces availability of Cardamyst on Express Scripts

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

Mar 20, 2026, 8:30 AM EDT - 7 weeks ago

Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-03-20T12:05:07.000Z - 7 weeks ago

Options Volatility and Implied Earnings Moves Today, March 20, 2026

XPEV ZGN

2026-03-20T11:21:41.000Z - 7 weeks ago

Milestone Pharmaceuticals reports Q4 EPS (16c), consensus (18c)

Mar 20, 2026, 7:12 AM EDT - 7 weeks ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

2026-03-16T12:23:37.000Z - 2 months ago

Milestone Pharmaceuticals to present Cardamyst data at ACC 26

Mar 16, 2026, 8:13 AM EDT - 2 months ago

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

Mar 3, 2026, 9:10 AM EST - 2 months ago

Milestone Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 8:00 AM EST - 2 months ago

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

2026-02-10T13:20:23.000Z - 3 months ago

Milestone Pharmaceuticals appoints Sandoval as General Counsel, CCO

Feb 10, 2026, 8:00 AM EST - 3 months ago

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

2026-02-03T13:25:44.000Z - 3 months ago

Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule

2026-01-26T13:10:09.000Z - 3 months ago

Milestone Pharmaceuticals announces U.S. availability of cardamyst

Jan 26, 2026, 8:00 AM EST - 3 months ago

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

2026-01-06T13:22:04.000Z - 4 months ago

Milestone announces acceptance of MAA by EMA for etripamil nasal spray

Jan 6, 2026, 8:00 AM EST - 4 months ago

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

2025-12-16T11:51:36.000Z - 5 months ago

Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo

2025-12-15T15:10:07.000Z - 5 months ago

Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval

2025-12-15T15:05:16.000Z - 5 months ago

Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen

2025-12-15T14:50:25.000Z - 5 months ago

Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright

Dec 15, 2025, 8:00 AM EST - 5 months ago

Milestone Pharmaceuticals Transcript: FDA Announcement

2025-12-14T16:30:25.000Z - 5 months ago

Milestone Pharmaceuticals receives FDA approval of CARDAMYST

Dec 12, 2025, 8:00 PM EST - 5 months ago

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

2025-12-12T23:10:17.000Z - 5 months ago

Milestone Pharmaceuticals trading halted, news pending

Nov 12, 2025, 7:01 AM EST - 6 months ago

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Nov 3, 2025, 8:00 AM EST - 6 months ago

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Oct 9, 2025, 8:00 AM EDT - 7 months ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Sep 9, 2025, 12:00 PM EDT - 8 months ago

Milestone Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 8:00 AM EDT - 9 months ago

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Aug 12, 2025, 7:05 AM EDT - 9 months ago

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Jul 11, 2025, 9:30 AM EDT - 10 months ago

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Jul 11, 2025, 6:01 AM EDT - 10 months ago

Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:00 AM EDT - 10 months ago

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Jun 5, 2025, 2:35 PM EDT - 1 year ago

Milestone Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 14, 2025, 7:04 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Mar 28, 2025, 10:24 AM EDT - 1 year ago

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

Mar 28, 2025, 7:06 AM EDT - 1 year ago

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Mar 28, 2025, 7:00 AM EDT - 1 year ago

FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Mar 13, 2025, 7:08 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Mar 4, 2025, 9:10 AM EST - 1 year ago

Milestone Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 10:30 AM EST - 1 year ago

Milestone Pharmaceuticals Transcript: Investor update

Feb 19, 2025, 8:00 AM EST - 1 year ago

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Feb 11, 2025, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Jan 28, 2025, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Nov 12, 2024, 9:03 AM EST - 1 year ago

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Aug 8, 2024, 4:17 PM EDT - 1 year ago

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Transcript: Study update

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

May 31, 2024, 8:00 AM EDT - 2 years ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 13, 2024, 7:15 AM EDT - 2 years ago

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Apr 8, 2024, 11:36 AM EDT - 2 years ago

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Mar 21, 2024, 7:14 AM EDT - 2 years ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Feb 29, 2024, 4:01 PM EST - 2 years ago

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Feb 28, 2024, 4:37 PM EST - 2 years ago

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

MarketBeat May. 13 at 6:11 PM

https://marketbeat.com/a/8652816/ $MIST Milestone Pharmaceuticals Q1 Earnings Call Highlights

0 · Reply

doctorhak May. 13 at 5:57 PM

0 · Reply

TheYoungGeologist May. 13 at 5:57 PM

$MIST now have 10000 shares in my brokerage and 7000 in my Roth IRA

1 · Reply

Wut_About_Bob May. 13 at 5:32 PM

0 · Reply

Amb8675309 May. 13 at 5:18 PM

$MIST really it’s a binary outcome for the next earnings call hiding inside of a slow, cash burn problem

0 · Reply

Amb8675309 May. 13 at 5:17 PM

$MIST the biggest driver for the share price will be if we get to see that 2000 to 3000 scripts on the next earning call

1 · Reply

Bolekjol May. 13 at 4:43 PM

0 · Reply

CashisKing_ May. 13 at 4:43 PM

$MIST when are we expecting china aproval?

1 · Reply

kellymone2 May. 13 at 4:36 PM

$MIST told ya. Panic doesn't bring anything.

0 · Reply

KilroyPicks May. 13 at 4:26 PM

1 · Reply

aak12345 May. 13 at 4:19 PM

$MIST don't see anything wrong with progress. Afib trial started (2 years to complete) Express scripts onboard already (others to follow soon) Scripts steadily rising in early data Ample cash reserves China +EU approval incoming

1 · Reply

Diverstj981 May. 13 at 4:17 PM

$MIST at the end of March there was a dead cat bounce before it bottomed. I'm sitting tight for a day or two longer before adding in case history repeats itself.

0 · Reply

Joe_BLow_88 May. 13 at 4:10 PM

$MIST 400 unique prescribers! that is an outstanding number. Actual April prescriptions 450, over about 150 to march 20. Their marketing scheme is working really well. Docs are prescribing. There's breadth in those numbers. This may hockey stick if they keep it up. and their burn rate is reasonable. No insurer push back, so far. Afib trial on the way. But they are Canadians. So I understand the hesitation. I'll hold for now.

1 · Reply

Amb8675309 May. 13 at 3:36 PM

$MIST after they were approved, people discussed pill in a pocket as a cheap alternative. Remember if you use super cheap PIP and you time how long it takes to bring your heart rate down and then you look at Cardamyst &amp; how many people end up having to use the 2nd dose before their heart rate goes back down there’s only a delta of approx 10 minutes. PIP is pennies on the dollar. Took advice of someone who didn’t understand what pill in the pocket was plus he thought that sales were going to be good. Do your own DD folks. this particular leadership team is sloppy( which is why they got their first CRL last year). Cardamyst has a tough uphill battle based on cost per dose vs PIP option. when people say this will cut down ER visits: by the time you’re waited 3 hours at the ER, you could’ve just used PIP and not had to pay $1500 for Cardamyst, and not had to go to ER. If you’re undiagnosed PVST/aFib, sure, go to ER. Will ER give you Cardamyst?

2 · Reply

Amb8675309 May. 13 at 3:22 PM

$MIST I asked someone if this was bec there’s pill in a pocket as a cheaper option- he hadn’t done the homework and told me he thought sakes would be great…. Learning to trust my own gut-

1 · Reply

KilroyPicks May. 13 at 2:16 PM

$MIST - https://www.minichart.com.sg/2026/04/28/everest-medicines-supplemental-announcement-on-discloseable-asset-purchase-agreement-and-psvt-nasal-spray-product-commercialization-12/

0 · Reply

durocali May. 13 at 2:15 PM

$MIST agreed. shares fell there less than 7 wks ago... and managed to double up in short order. market knows the potential here. and yes 2H26 and likely greater upside in 2027-28... here for it.

1 · Reply

KilroyPicks May. 13 at 2:14 PM

$MIST https://www.biospectrumasia.com/news/25/27391/everest-medicines-inks-50-m-deal-with-corxel-pharma-to-develop-nasal-spray-in-greater-china.html

0 · Reply

KilroyPicks May. 13 at 2:12 PM

$MIST https://www.tipranks.com/news/company-announcements/everest-medicines-details-psvt-asset-purchase-and-readies-for-china-launch

0 · Reply

KilroyPicks May. 13 at 2:12 PM

$MIST - Everest Medicines will pay a royalty payment of $105 Million was drug gets China approval which is expected in Q3.

0 · Reply

kgstocker68 May. 13 at 2:11 PM

$MIST Wow, pretty light sales so far. This might be a very slow trek uphill. Will Q2 break $1M?

2 · Reply

Vincybull May. 13 at 2:11 PM

$MIST Did they say when phase 3 of the AFib RvR trial will start? They said for the apoeovaion in CHINA. Who said that 30M were expected for this quarter? There is great manipulation, those great sons of . .

1 · Reply

Market Cap	227.31M
Revenue (ttm)	1.55M
Net Income (ttm)	-63.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,068.39%
Debt to Equity Ratio	0.00

Volume	5,212,924
Avg Vol	2,072,334
Day's Range	N/A - N/A
Shares Out	119.64M
Stochastic %K	53%
Beta	1.04
Analysts	Strong Sell
Price Target	$6.50